Farxiga Data Change Heart Failure Treatment Outlook
Executive Summary
DAPA-HF data on AstraZeneca’s SGLT-2 inhibitor dapagliflozin as a treatment for heart failure in both diabetics and non-diabetics won spontaneous applause at ESC.
You may also be interested in...
Cardiology Could Get A Jolt As FDA Reviews Novel Heart Failure Candidates From BMS, Cytokinetics
Upcoming US FDA decisions could bring breakthrough-designated approvals for BI/Lilly’s Jardiance in heart failure with preserved ejection fraction and BMS’ mavacamten in hypertrophic cardiomyopathy, while Cytokinetics bids to bring a new mechanism the busy heart failure with reduced ejection fraction space and earns a BTD in HCM.
BI/Lilly's Jardiance Takes On AstraZeneca's Farxiga With Heart Failure Approval
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.